Hematology CrossTalk

In the second episode of Hematology CrossTalk, Dr. Gianluca Rotta (Waters™ Biosciences, formerly BD Biosciences) continues the discussion with Prof. Francesco Buccisano (Tor Vergata University of Rome, Italy) and Dr. Vittorio Emanuele Muccio (San Luigi Gonzaga University Hospital, Orbassano, Italy), exploring the evolving role of measurable residual disease (MRD) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes(MDS).The conversation looks at how MRD assessment is redefining the definition of complete remission and influencingclinical decision-making. From the laboratory perspective, the experts discuss the challenges of increasing sensitivity, distinguishing normal from abnormal cell populations, and ensuring reproducible results through standardized workflows and expert interpretation.The discussion also looks ahead to the future of MRD assessment, paving the way for next-generation flow cytometrytechnologies, automated gating and artificial intelligence (AI) supported analysis, while reinforcing the importance of collaboration between laboratory and clinical experts in translating increasingly precise data into patient care.Access the discussion highlights and discover more:https://lp.bd.com/202609-BDB26-EMEA_EN-Clinical-AWAR-FlowF_NA_Podcast-ValProp-BDcom-Form_2_LP-EN-01-MainLP.htmlAll contents are and should be understood as informative in nature and do not discuss, endorse or recommend any specific test, technology, or clinical action.Supported by Waters™ Biosciences (formerly BD Biosciences).

Welcome to the first episode of Hematology CrossTalk, a new podcast bringing together experts from across hematology to explore the challenges shaping clinical practice and laboratory diagnostics.Hosted by Dr. Gianluca Rotta (Waters™ Biosciences, formerly BD Biosciences), the episode features Prof. Francesco Buccisano and Dr. Vittorio Emanuele Muccio, bringing together clinical and laboratory expertise in flow cytometryand hematology.Prof. Francesco Buccisano is Associate Professor of Hematology at Tor Vergata University of Rome, Italy, and Director of Immunohematology and Transfusion Medicine at the Tor Vergata Polyclinic. He is an internationally recognized expert in flow cytometry and leads a reference center for the diagnosis and assessment of measurable residual disease (MRD) in AML.Dr. Vittorio Emanuele Muccio is a ClinicalPathology Specialist and Senior Biologist in the Flow Cytometry and Protein Diagnostics Unit at San Luigi Gonzaga University Hospital in Orbassano, Italy. His expertise includes diagnostic flow cytometry, oncohematology, immunophenotyping and MRD assessment, with a particular focus on the standardization and harmonization of flow cytometry and laboratory workflows.In this episode they explore the evolving role of flow cytometry in the diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), highlighting the shift from morphology-based assessment to a more integrateddiagnostic approach. They discuss complex diagnostic cases, laboratory workflows and the importance of clear, standardized reporting.The discussion underscores how technology, standardization and collaboration can help improve patient care.Access the discussion highlights and discover the next episode: https://bit.ly/4xCrRcz All contents are and should be understood as informative in nature and do not discuss, endorse or recommend any specific test, technology, or clinical action.Supported by Waters™ Biosciences (formerly BD Biosciences).